Matritech to Present at Roth Capital Partners 19th Annual OC Conference.NEWTON, Mass. -- Matritech, Inc. (Amex: MZT MZT Mazatlan, Sinaloa, Mexico - Buelna (Airport Code) MZT Main Zagros Thrust ), a leading developer and marketer of protein-based diagnostic products for the early detection of cancer, announced today that Stephen D. Chubb, Chairman and Chief Executive Officer, will be presenting at the Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, 19th Annual OC Conference on Wednesday, February 21, 2007 at 9:00 a.m. Pacific time (Noon, Eastern). The conference, to be held at the Ritz-Carlton Laguna Niguel Hotel in Laguna Niguel, California Laguna Niguel is a city located in southern Orange County, California. The name "Laguna Niguel" is derived from the Spanish word "Laguna" which means lagoon and the word "Nigueli" which was the name of a Juaneno Indian village once located on Aliso Creek. is one of the country's largest institutional investor conferences for micro- and small-cap companies with presentations from nearly 300 companies. Mr. Chubb's presentation will be webcast live and can be accessed on the investor section of the Matritech website at www.matritech.com. About Matritech Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22[R]Test Kit and the NMP22[R] BladderChek([R]) Test, have been FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved for the monitoring and diagnosis of bladder cancer. The NMP22[R]BladderChek([R]) Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, (MIT MIT - Massachusetts Institute of Technology ), Matritech's patent portfolio has grown to more than 14 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22[R] Test Kit and the NMP22[R] BladderChek([R]) Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company's goal is to utilize these protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion